{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021203","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.822852+00:00","generated_at":"2026-06-15T04:14:19.470639+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kezar Life Sciences Q1 2023 net loss $22.2M; cash $257.7M; trials on track","bullets":["Net loss of $22.2M ($0.31 per share) vs $16.0M ($0.26 per share) in Q1 2022.","Cash, cash equivalents and marketable securities $257.7M as of March 31, 2023, down from $276.6M at Dec 31, 2022.","R&D expenses increased to $18.3M from $10.9M, driven by advancing zetomipzomib and KZR-261 programs.","PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis on track to initiate in H1 2023.","KZR-261 dose escalation study enrolling Cohort 6; dose expansion expected H2 2023 with topline data mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021203","json":"https://secwatch.observer/filing/0000950170-23-021203.json","markdown":"https://secwatch.observer/filing/0000950170-23-021203.md","text":"https://secwatch.observer/filing/0000950170-23-021203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023021203/0000950170-23-021203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023021203/kzr-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:14:19.470639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19da587e2c4e6a168582a4c8a4e531b7c92606fb","claim":"Kezar Life Sciences, Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023021203/0000950170-23-021203-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}